Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockBearish
0
Neutral
13
Bullish
1
Bearish
8
Neutral
37
Bullish
1
Bearish
8
Neutral
24
Bullish
0
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Ganga Pharmaceuticals Ltd manufactures and trades ayurvedic pharmaceuticals, focusing on traditional medicine with a modern approach.
Established in 1994, the company took over an existing ayurvedic business in 1995, signifying a strong foundation in traditional medicine.
The company has a global presence, exporting its products to countries in the Middle East and Europe, indicating a robust international market penetration.
It has invested in expanding manufacturing capabilities, emphasizing a commitment to innovation and meeting increasing demand.
Despite its extensive history, the absence of recent strategic updates raises questions about its current competitive positioning.
Pharmaceuticals & Biotechnology
Pharmaceuticals
7 Cr
High Risk
100.0
32.0
3.6
0.9
14.80
9.25
Sales CAGR
Profit CAGR
ROE
ROCE
Ganga Pharmaceuticals Ltd (GANGAPHARM) is currently trading at N/A per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Ganga Pharmaceuticals Ltd manufactures and trades ayurvedic pharmaceuticals, focusing on traditional medicine with a modern approach. Established in 1994, the company took over an existing ayurvedic business in 1995, signifying a strong foundation in traditional medicine. The company has a global presence, exporting its products to countries in the Middle East and Europe, indicating a robust international market penetration. It has invested in expanding manufacturing capabilities, emphasizing a commitment to innovation and meeting increasing demand. Despite its extensive history, the absence of recent strategic updates raises questions about its current competitive positioning.
Over the past 52 weeks, Ganga Pharmaceuticals Ltd has traded between a low of ₹9.25 and a high of ₹14.80. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Ganga Pharmaceuticals Ltd has a market capitalization of approximately 7.09. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Ganga Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 100.00 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 7.09 Cr, Ganga Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Ganga Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Ganga Pharmaceuticals Ltd is 100.00. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Investor Presentation
Q4 FY24
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Change in Directors/KMP
Board approved re-appointment of Mr. Bharat Brijmohan Sharma (DIN: 00077026) as Managing Director for three years from April 01, 2026, not liable to retire by rotation, subject to shareholder approval; recommended by NRC & Audit Committee (Board meeting 10-Mar-2026).
Change in Directors/KMP
The Board of Ganga Pharmaceuticals approved re-appointment of Mr. Bharat Brijmohan Sharma (DIN:00077026) as Managing Director for three years effective April 1, 2026, subject to members' approval; he is not debarred.
Change in Directors/KMP
Board of Ganga Pharmaceuticals approved re-appointment of Mr. Bharat Brijmohan Sharma (DIN: 00077026) as Managing Director for three years effective April 1, 2026, subject to shareholder approval; not liable to retire by rotation and not debarred.
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
20.20 | 10 Cr | 673.33 | 1.08 | 0.00 | 2.47 | 7.06 | 0.06 | |
20.00 | 9 Cr | 8.51 | 2.06 | 0.00 | 23.59 | 26.37 | 16.12 | |
1.95 | 8 Cr | -48.75 | 1.69 | 0.00 | -6.62 | -0.04 | -0.30 | |
12.00 | 7 Cr | 100.00 | 0.89 | 0.00 | 0.96 | 2.20 | 0.79 | |
6.11 | 6 Cr | -0.77 | 0.32 | 0.00 | -42.34 | -50.18 | -33.92 | |
20.20 | 6 Cr | -59.41 | 1.90 | 0.00 | — | — | 0.00 | |
41.50 | 5 Cr | 21.17 | 0.60 | 0.00 | 4.69 | 5.88 | 4.04 | |
| Median: 7 Co. | 20.00 | 7 Cr | 8.51 | 1.08 | 0.00 | 1.72 | 4.04 | 0.06 |
